ProMIS Neurosciences, Inc. (PMN) Balance Sheet
PMN balance sheet, 2025
December 31, 2025 · U.S. dollars$9.2M assets = $10.4M liabilities + −$1.3M equity
Liabilities exceed assets: shareholders’ equity is negative (−$1.3M).
Both columns are drawn to the same scale: what PMN owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PMN financial health
Descriptive bands, not a rating. Fiscal 2025.
PMN balance sheet trends, 2023–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $13.6M2023 | $9.2M2025 | −17.9%/yr | |
| Total liabilities | $9.9M2023 | $10.4M2025 | +2.9%/yr | |
| Shareholders’ equity | $3.8M2023 | −$1.3M2025 | — | |
| Cash & short-term investments | $12.6M2023 | $6.2M2025 | −30.2%/yr | |
| Working capital | $4.3M2023 | −$1.2M2025 | −$5.5M | |
| Current ratio | 1.462023 | 0.882025 | −0.57 |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PMN assets
PMN liabilities and equity
PMN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PMN balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Assets | |||
| Cash & short-term investments | $6.2M | $13.3M | $12.6M |
| Cash & equivalents | $6.1M | $13.3M | $12.6M |
| Short-term investments | $33,753 | $33,051 | $32,358 |
| Receivables | $36,522 | $78,034 | $78,637 |
| Inventory | $0 | $0 | $0 |
| Other current assets | $3.0M | $5.5M | $910,004 |
| Total current assets | $9.2M | $18.9M | $13.6M |
| Property, plant & equipment (net) | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 |
| Other non-current assets | $0 | $0 | $0 |
| Total assets | $9.2M | $18.9M | $13.6M |
| Liabilities | |||
| Accounts payable | $2.5M | $1.7M | $7.8M |
| Total current liabilities | $10.4M | $2.2M | $9.3M |
| Long-term debt | $0 | $0 | $0 |
| Other long-term liabilities | $29,182 | $204,855 | $516,187 |
| Total liabilities | $10.4M | $2.4M | $9.9M |
| Shareholders' equity | |||
| Retained earnings (deficit) | −$130.4M | −$90.7M | −$93.5M |
| Accumulated other comprehensive income | −$371,184 | −$371,184 | −$371,184 |
| Total shareholders' equity | −$1.3M | $16.5M | $3.8M |
| Key figures | |||
| Working capital | −$1.2M | $16.7M | $4.3M |
| Tangible book value | −$1.3M | $16.5M | $3.8M |
| Current ratio | 0.88 | 8.52 | 1.46 |
| Quick ratio | 0.59 | 6.04 | 1.36 |
| Equity / assets | −13.7% | 87.2% | 27.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $53.5M | $63.8M | $6.2M | $15.4M | $4.5M | $8.4M | $13.3M | $21.6M | $1.0M | $2.5M |
| Cash & equivalents | $53.4M | $63.8M | $6.1M | $15.4M | $4.5M | $8.4M | $13.3M | $21.5M | $992,463 | $2.5M |
| Short-term investments | $33,753 | $33,753 | $33,753 | $33,050 | $33,051 | $33,051 | $33,051 | $32,358 | $32,358 | $32,358 |
| Receivables | $0 | $238,329 | $36,522 | $86,065 | $29,484 | $54,557 | $78,034 | $630,283 | $72,255 | $76,805 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1 | −$76,805 |
| Other current assets | $3.2M | $1.5M | $3.0M | $5.9M | $4.9M | $5.2M | $5.5M | $2.3M | $312,520 | $1.0M |
| Total current assets | $56.7M | $65.6M | $9.2M | $21.5M | $9.5M | $13.6M | $18.9M | $24.5M | $1.4M | $3.5M |
| Property, plant & equipment (net) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill & intangible assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-term investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $0 | $1.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total assets | $56.7M | $67.4M | $9.2M | $21.5M | $9.5M | $13.6M | $18.9M | $24.5M | $1.4M | $3.5M |
| Liabilities | ||||||||||
| Accounts payable | $1.8M | $1.7M | $2.5M | $4.2M | $2.8M | $1.2M | $1.7M | $1.6M | $2.0M | $1.4M |
| Total current liabilities | $7.2M | $6.6M | $10.4M | $12.2M | $9.8M | $4.1M | $2.2M | $2.6M | $3.2M | $2.6M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other long-term liabilities | $77,255 | $79,380 | $29,182 | $59,744 | $67,987 | $118,692 | $204,855 | $14.6M | $514,719 | $825,287 |
| Total liabilities | $7.3M | $6.7M | $10.4M | $12.3M | $9.9M | $4.2M | $2.4M | $17.2M | $3.7M | $3.5M |
| Shareholders' equity | ||||||||||
| Retained earnings (deficit) | −$150.4M | −$138.7M | −$130.4M | −$119.7M | −$108.2M | −$98.0M | −$90.7M | −$90.4M | −$99.7M | −$97.1M |
| Accumulated other comprehensive income | −$371,184 | −$371,184 | −$371,184 | −$371,184 | −$371,184 | −$371,184 | −$371,184 | −$371,184 | −$371,184 | −$371,184 |
| Total shareholders' equity | $49.4M | $60.7M | −$1.3M | $9.2M | −$382,578 | $9.5M | $16.5M | $7.3M | −$2.3M | $77,099 |
| Key figures | ||||||||||
| Working capital | $49.5M | $59.0M | −$1.2M | $9.2M | −$314,591 | $9.6M | $16.7M | $21.9M | −$1.8M | $902,386 |
| Tangible book value | $49.4M | $60.7M | −$1.3M | $9.2M | −$382,578 | $9.5M | $16.5M | $7.3M | −$2.3M | $77,099 |
| Book value per share | $5.40 | $9.30 | — | — | — | — | — | — | — | — |
| Shares outstanding | 9.1M | 6.5M | — | — | — | — | — | — | — | — |
| Current ratio | 7.85 | 9.92 | 0.88 | 1.76 | 0.97 | 3.36 | 8.52 | 9.30 | 0.44 | 1.34 |
| Quick ratio | 7.41 | 9.69 | 0.59 | 1.27 | 0.47 | 2.08 | 6.04 | 8.42 | 0.35 | 0.98 |
| Equity / assets | 87.1% | 90.1% | −13.7% | 42.8% | −4.0% | 69.4% | 87.2% | 29.7% | −161.5% | 2.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed March 25, 2026); data from EODHD.
PMN financial position
At the end of fiscal 2025 (December 31, 2025), ProMIS Neurosciences had total assets of $9.2 million (down 51.4% from a year earlier), total liabilities of $10.4 million and shareholders' equity of -$1.3 million. Its current ratio was 0.88. In the latest quarter (ended June 30, 2026) total assets were $56.7 million and equity $49.4 million.
Related: PMN income statement, PMN cash flow statement, PMN key metrics. See the PMN stock overview for the latest quote and news.
PMN balance sheet FAQ
What are ProMIS Neurosciences's total assets?
ProMIS Neurosciences reported total assets of $9.2 million at the end of fiscal 2025 (December 31, 2025), compared with $18.9 million a year earlier.
How much cash does ProMIS Neurosciences have?
ProMIS Neurosciences held $6.2 million in cash and short-term investments at the end of fiscal 2025.
What is ProMIS Neurosciences's book value?
ProMIS Neurosciences's shareholders' equity (book value) was -$1.3 million at the end of fiscal 2025.
What is ProMIS Neurosciences's current ratio?
ProMIS Neurosciences had current assets of $9.2 million and current liabilities of $10.4 million, a current ratio of 0.88 (current liabilities exceed current assets).